NPI: 1871010280 · ARROYO GRANDE, CA 93420 · Clinic/Center · NPI assigned 08/25/2017
Authorized official ALLEN, BARBARA controls 15+ related entities in our dataset. Read more
| Authorized Official | ALLEN, BARBARA (BUSINESS OFFICE MANAGER) |
| NPI Enumeration Date | 08/25/2017 |
Other providers sharing the same authorized official: ALLEN, BARBARA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 20,397 | $869K |
| 2019 | 36,990 | $1.17M |
| 2020 | 40,088 | $1.08M |
| 2021 | 45,960 | $1.34M |
| 2022 | 37,504 | $1.48M |
| 2023 | 33,754 | $1.67M |
| 2024 | 21,043 | $1.34M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| T1015 | Clinic visit/encounter, all-inclusive | 50,556 | 47,396 | $7.35M |
| 0521 | 100,396 | 39,607 | $1.24M | |
| 0301 | 2,241 | 2,203 | $125K | |
| 0309 | 5,081 | 4,938 | $60K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,651 | 2,887 | $56K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33,011 | 30,784 | $22K |
| 0636 | 2,320 | 2,085 | $20K | |
| 99051 | 9,654 | 9,426 | $13K | |
| 0771 | 392 | 386 | $11K | |
| 0412 | 708 | 686 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4,551 | 3,711 | $9K |
| 0307 | 3,695 | 3,173 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2,204 | 1,655 | $8K |
| 0271 | 1,784 | 1,709 | $6K | |
| 0306 | 491 | 489 | $6K | |
| 0761 | 242 | 240 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2,154 | 2,094 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1,263 | 1,045 | $966.52 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1,150 | 1,098 | $278.65 |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 289 | 284 | $217.48 |
| 71046 | Radiologic examination, chest; 2 views | 42 | 41 | $164.83 |
| 81003 | 237 | 173 | $156.37 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2,846 | 2,757 | $111.30 |
| 81000 | 2,472 | 2,417 | $60.22 | |
| 81025 | 184 | 180 | $6.58 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 21 | 13 | $0.13 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 2,124 | 2,086 | $0.00 |
| 99000 | 79 | 79 | $0.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1,116 | 1,067 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 33 | 33 | $0.00 |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 60 | 59 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 12 | 12 | $0.00 |
| 69209 | 87 | 87 | $0.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 538 | 530 | $0.00 |
| 99173 | 37 | 37 | $0.00 | |
| 73630 | 15 | 14 | $0.00 |